On March 25, the National Medical Products Administration (NMPA) officially announced that the Recombinant Type A Botulinum Toxin for Injection (National Drug Approval No. S20260019), developed by Chongqing Yuyan Pharmaceutical Co., Ltd. (a subsidiary of MingMed), has been approved for market. This is China's first and the world's first recombinant technology-produced Type A botulinum toxin, marking a core technological breakthrough in the botulinum toxin field for China and breaking the long-standing monopoly of imported products.

Unlike traditional botulinum toxin fermentation processes using Clostridium botulinum, this product utilizes an E. coli expression system, completely eliminating the risks associated with pathogenic bacterial culture. The product is a 150kDa single-component neurotoxin, free from complex protein impurities, offering higher purity, lower immunogenicity, and significantly better clinical safety compared to traditional products.

This approval is not only a landmark breakthrough for China's biopharmaceutical technology but is also poised to reshape the global botulinum toxin market landscape, drive industrial upgrading in China's medical aesthetics and neuromuscular disease treatment sectors, and provide safer, higher-quality treatment options for patients worldwide.

Efung Capital invested in MingMed in 2021, providing financial support and continuously empowering the company through industrial resource connections. Looking ahead,Efung Capital will continue to deeply cultivate the biopharmaceutical field, support the growth of more innovative companies with global competitiveness, and propel Chinese innovative drugs onto a broader international stage.